Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Kolb

Showing results (51-60 of 279) with videos related to

Pageof 28
Sort By:
Expert Opinion on Emerging Drugs|April 8, 2024
Treatment of idiopathic pulmonary fibrosis: an update on emerging drugs in phase II & III clinical trialsSarah MacIsaac, Dujrath Somboonviboon, Ciaran Scallan, et al.
Current Pharmaceutical Design|February 7, 2003
Re-evaluation of fibrogenic cytokines in lung fibrosisMargaret Kelly, Martin Kolb, Phillipe Bonniaud, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|September 13, 2019
What have we learned from basic science studies on idiopathic pulmonary fibrosis?Toyoshi Yanagihara, Seidai Sato, Chandak Upagupta, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|June 29, 2018
Matrix abnormalities in pulmonary fibrosisChandak Upagupta, Chiko Shimbori, Rahmah Alsilmi, et al.
American Journal of Respiratory Cell and Molecular Biology|November 9, 2010
Pulmonary hypertension and idiopathic pulmonary fibrosis: a tale of angiogenesis, apoptosis, and growth factorsLaszlo Farkas, Jack Gauldie, Norbert F Voelkel, et al.
The European Respiratory Journal|October 3, 2020
Inflammation and intussusceptive angiogenesis in COVID-19: everything in and out of flowMaximilian Ackermann, Steven J Mentzer, Martin Kolb, et al.
The International Journal of Biochemistry & Cell Biology|September 2, 2019
Fibrocytes and fibroblasts-Where are we nowSy Giin Chong, Seidai Sato, Martin Kolb, et al.
Expert Opinion on Therapeutic Targets|December 8, 2020
HSP47: a potential target for fibrotic diseases and implications for therapyPierre-Simon Bellaye, Olivier Burgy, Philippe Bonniaud, et al.
The European Respiratory Journal|February 25, 2017
Heat shock protein: a hot topic in idiopathic pulmonary fibrosisPhilippe Bonniaud, Pierre-Simon Bellaye, Olivier Burgy, et al.
Proceedings of the American Thoracic Society|June 2, 2006
Targeting genes for treatment in idiopathic pulmonary fibrosis: challenges and opportunities, promises and pitfallsKjetil Ask, Gail E M Martin, Martin Kolb, et al.
Pageof 28

Showing results (51-60 of 279) with videos related to

Sort By:
Pageof 28
Expert Opinion on Emerging Drugs|April 8, 2024
Treatment of idiopathic pulmonary fibrosis: an update on emerging drugs in phase II & III clinical trialsSarah MacIsaac, Dujrath Somboonviboon, Ciaran Scallan, et al.
Current Pharmaceutical Design|February 7, 2003
Re-evaluation of fibrogenic cytokines in lung fibrosisMargaret Kelly, Martin Kolb, Phillipe Bonniaud, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|September 13, 2019
What have we learned from basic science studies on idiopathic pulmonary fibrosis?Toyoshi Yanagihara, Seidai Sato, Chandak Upagupta, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|June 29, 2018
Matrix abnormalities in pulmonary fibrosisChandak Upagupta, Chiko Shimbori, Rahmah Alsilmi, et al.
American Journal of Respiratory Cell and Molecular Biology|November 9, 2010
Pulmonary hypertension and idiopathic pulmonary fibrosis: a tale of angiogenesis, apoptosis, and growth factorsLaszlo Farkas, Jack Gauldie, Norbert F Voelkel, et al.
The European Respiratory Journal|October 3, 2020
Inflammation and intussusceptive angiogenesis in COVID-19: everything in and out of flowMaximilian Ackermann, Steven J Mentzer, Martin Kolb, et al.
The International Journal of Biochemistry & Cell Biology|September 2, 2019
Fibrocytes and fibroblasts-Where are we nowSy Giin Chong, Seidai Sato, Martin Kolb, et al.
Expert Opinion on Therapeutic Targets|December 8, 2020
HSP47: a potential target for fibrotic diseases and implications for therapyPierre-Simon Bellaye, Olivier Burgy, Philippe Bonniaud, et al.
The European Respiratory Journal|February 25, 2017
Heat shock protein: a hot topic in idiopathic pulmonary fibrosisPhilippe Bonniaud, Pierre-Simon Bellaye, Olivier Burgy, et al.
Proceedings of the American Thoracic Society|June 2, 2006
Targeting genes for treatment in idiopathic pulmonary fibrosis: challenges and opportunities, promises and pitfallsKjetil Ask, Gail E M Martin, Martin Kolb, et al.
Pageof 28